NASDAQ
15.12.25 | 21:59
2,440 US-Dollar
-1,21 % -0,030
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.12. | C4 Therapeutics: TD Cowen startet Coverage mit Kaufempfehlung | 1 | Investing.com Deutsch | ||
| 02.12. | C4 Therapeutics stock initiated with Buy rating at TD Cowen | 1 | Investing.com | ||
| 21.11. | C4 Therapeutics files $400M mixed shelf offering | 2 | Seeking Alpha | ||
| 06.11. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.11. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 16.10. | C4 Therapeutics prices $125M equity offering with warrants | 6 | Seeking Alpha | ||
| 16.10. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering | 5 | GlobeNewswire (USA) | ||
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 16.10. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma | 161 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 01.10. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.09. | C4 Therapeutics stock price target raised to $10 by Wells Fargo on positive data | 10 | Investing.com | ||
| 23.09. | C4 Therapeutics: Wells Fargo verdoppelt Kursziel nach positiven Studiendaten | 5 | Investing.com Deutsch | ||
| 22.09. | Forecasting The Future: 4 Analyst Projections For C4 Therapeutics | 4 | Benzinga.com | ||
| 22.09. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.09. | Myelom-Medikament von C4 Therapeutics zeigt 50-prozentige Ansprechrate in Studie | 1 | Investing.com Deutsch | ||
| 20.09. | C4 Therapeutics Reports Promising Phase 1 Results For Cemsidomide In R/R Multiple Myeloma | 1 | RTTNews | ||
| 20.09. | C4 Therapeutics' myeloma drug shows 50% response rate in trial | 2 | Investing.com | ||
| 20.09. | C4 Therapeutics, Inc.: C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 16.09. | Barclays bestätigt "Overweight"-Rating für C4 Therapeutics | 1 | Investing.com Deutsch | ||
| 16.09. | C4 Therapeutics stock rating reiterated as Overweight by Barclays | 3 | Investing.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,950 | +0,52 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| OCUGEN | 1,178 | -0,08 % | Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit | ||
| CELLDEX THERAPEUTICS | 23,000 | -0,86 % | Celldex Therapeutics, Inc.: Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism | No advanced therapies approved to treat ColdU and SD-diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in development to demonstrate clinical benefit... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,040 | 0,00 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,148 | -3,37 % | Coherus Oncology, Inc.: Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | - Responsible for Corporate Development, Investor Relations, Government Affairs - REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that... ► Artikel lesen | |
| NEOVACS | 0,011 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 18.07.2025 | The following instruments on XETRA do have their first trading 18.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.07.2025
Aktien
1 KYG7388C1033 Qunabox Group Ltd.
2... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 7,250 | -2,82 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| ULTRAGENYX | 30,600 | -0,65 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita (burosumab) for $400 Million to OMERS Life Sciences | Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55... ► Artikel lesen | |
| GYRE THERAPEUTICS | 6,750 | +4,65 % | Gyre Therapeutics Inc.: Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update | Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to $115-118 million (from $118 - $128 million... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 5,150 | 0,00 % | Sagimet Biosciences Inc.: Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration | SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic... ► Artikel lesen | |
| GOSSAMER BIO | 3,144 | -2,90 % | Respira Therapeutics, Inc.: Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital | - Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and... ► Artikel lesen | |
| BIOMEA FUSION | 1,345 | -4,61 % | Biomea Fusion, Inc.: Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 | ||
| JANUX THERAPEUTICS | 15,110 | 0,00 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 0,797 | -6,24 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy | SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen | |
| GENERATION BIO | 5,410 | 0,00 % | XOMA Royalty to acquire Generation Bio |
C4 THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,030 (-1,21 %) liegt der Kurs bei 2,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.